Literature DB >> 25975636

Bevacizumab: the phoenix of breast oncology?

Fabrice Andre1, Elise Deluche2, Herve Bonnefoi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25975636     DOI： 10.1016/S1470-2045(15)70201-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.

Authors:  Sara M Tolaney; Yves Boucher; Dan G Duda; John D Martin; Giorgio Seano; Marek Ancukiewicz; William T Barry; Shom Goel; Johanna Lahdenrata; Steven J Isakoff; Eren D Yeh; Saloni R Jain; Mehra Golshan; Jane Brock; Matija Snuderl; Eric P Winer; Ian E Krop; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 2.  The role of taxanes in triple-negative breast cancer: literature review.

Authors:  Giorgio Mustacchi; Michelino De Laurentiis
Journal:  Drug Des Devel Ther       Date:  2015-08-05       Impact factor: 4.162

3.  Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.

Authors:  Stefan-Alexandru Artene; Adina Turcu-Stiolica; Richard Hartley; Marius Eugen Ciurea; Oana Daianu; Corina Brindusa; Oana Alexandru; Ligia Gabriela Tataranu; Stefana Oana Purcaru; Anica Dricu
Journal:  Onco Targets Ther       Date:  2016-11-04       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.